CND Life Sciences, a neurodiagnostics company focused on objective biomarker-based testing for neurodegenerative diseases, announced on Aug. 4, 2026, the completion of a growth financing round led by S-Curve Partners. The transaction was joined by current CND investors and shareholders, signaling continued confidence in the company’s commercial trajectory and clinical adoption of its precision neurology mission. This influx of capital positions CND to scale its operations amid rising demand for earlier diagnosis and multimodal biomarkers in neurology.

The financing is intended to support sustained growth of the Syn-One Test platform, expand commercial initiatives, drive product innovation, and forge strategic partnerships. CND plans to incorporate the Syn-One Test into a broader multimodal biomarker capability designed to support clinical diagnosis and disease characterization of neurodegenerative disorders. The move aligns with heightened industry interest in objective biomarkers and precision medicine approaches within the neurology sector.

Rick Morello, Chief Executive Officer of CND Life Sciences, stated that the company is pleased to deepen its relationship with S-Curve Partners. He noted that S-Curve’s confidence reflects the progress made by the team in expanding clinical adoption and advancing the science behind the scalable neurodiagnostics platform. Morello emphasized gratitude for the continued support of existing investors and shareholders during this expansion phase.

Todd Levine, MD, Chief Medical Officer and Co-Founder at CND Life Sciences, highlighted the shift toward multimodal biomarkers and earlier intervention in neuroscience. He indicated that the financing provides flexibility to invest in innovation, expand access to the Syn-One platform, and strengthen relationships with pharmaceutical companies and research institutions. Levine’s comments underscore the strategic importance of the capital for future R&D and market penetration efforts.

Platform Adoption Metrics

The Syn-One Test is the first commercially available skin biopsy-based laboratory developed test (LDT) designed to detect abnormal, or phosphorylated, alpha-synuclein and other pathological markers. It assists clinicians in evaluating patients with suspected Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, REM sleep behavior disorder, and related synucleinopathies.

Since 2020, more than 4,000 neurologists and other clinicians across the United States have used the Syn-One Test to support the diagnostic evaluation of more than 60,000 patients. The platform is supported by a growing body of peer-reviewed clinical evidence assessing cutaneous phosphorylated alpha-synuclein as a biomarker of synucleinopathies.

Investor Perspective

Daniel Livschutz, Founding Partner of S-Curve Partners, described neurodegenerative diseases as among the most underdiagnosed and misdiagnosed conditions in medicine. He stated that as disease-modifying therapies emerge, objective biomarkers will become increasingly essential for clinicians, patients, researchers, and pharmaceutical companies. Livschutz expressed belief that CND has built one of the most differentiated platforms in neurodiagnostics, aiming to accelerate its evolution from a category-defining product to a broader platform supporting earlier diagnosis and personalized care.

S-Curve Partners is an operator-led healthcare investment firm focused on founder-inspired healthcare technology and diagnostics businesses. The firm combines strategic resources, operational expertise, and deep industry relationships to help companies scale, guided by former founders and operators who have successfully built and exited healthcare businesses.